Therefore, new therapeutic targets have been investigated, and TFAM is a strong candidate target since its expression is altered in several types of cancer, including glioma [13,15], colorectal cancer [63], epithelial ovarian carcinoma [66], bladder cancer [67], breast cancer [68], lung cancer [41,69], and colon cancer [70]. This evidence concerns the gene TFAM and urinary bladder cancer.